Axsome Therapeutics (AXSM) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 94.2% versus a gain of 43.3%. Over five years, AXSM leads with a +324.1% price change compared with +91.1% for KYMR. Kymera Therapeutics is the larger company by market cap ($9.25 billion vs $8.82 billion), about 1.0 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs -16.7%).
Axsome Therapeutics converts more of its revenue into profit, with a net margin of -28.7% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | KYMR |
|---|---|---|
| Share price | $168.35 | $112.40 |
| Market cap | $8.82B | $9.25B |
| 1-day change | -1.02% | +2.84% |
| YTD return | -6.88% | +40.47% |
| 1-year return | +43.27% | +94.17% |
| 5-year return | +324.14% | +91.08% |
| Forward P/E | 35.80 | — |
| EPS (TTM) | $-3.74 | $-3.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $39.21M |
| Revenue growth (YoY) | +65.55% | -16.70% |
| Net income (latest FY) | $-183.17M | $-311.35M |
| Gross margin | 92.56% | 0.00% |
| Operating margin | -26.12% | -891.07% |
| Net margin | -28.69% | -794.04% |
| 52-week high | $260.19 | $130.05 |
| 52-week low | $119.20 | $55.26 |
| Distance from 52-week high | -35.30% | -13.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.07% | +23.95% |
| Average volume | 712.30K | 705.63K |
| Shares outstanding | 52.38M | 82.26M |
| Employees | 1,346 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed AXSM by 50.9 percentage points over the past year.
- Axsome Therapeutics is more profitable, keeping -28.7 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs -16.70%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
AXSM vs KYMR FAQ
Which is bigger, Axsome Therapeutics or Kymera Therapeutics?
Kymera Therapeutics (KYMR) is larger, with a market capitalization of $9.25B compared with $8.82B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or KYMR?
KYMR returned +94.17% over the past 12 months, compared with +43.27% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Kymera Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Axsome Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Kymera Therapeutics.